Mustang Bio, Inc. Overview
Pro stress-test →Mustang Bio is a clinical-stage biopharmaceutical company focused on translating cell therapies into cures for difficult-to-treat cancers and autoimmune diseases in the United States. The company has partnered with top medical institutions to advance the development of CAR-T therapies, with MB-106 as its lead clinical candidate.
Strategic Profile
Pro stress-test →Mustang was founded by Fortress Biotech, Inc. The company operates a licensing and partnership model, acquiring rights to cell and gene therapy technologies and advancing them through clinical development. As of June 2, 2026, Mustang Bio has a market capitalization of $5.77 million, reflecting significant shareholder dilution from its peak, though the company continues advancing multiple clinical programs.
Competitive Landscape
Pro stress-test →Mustang competes in the cell therapy/CAR-T space against better-capitalized public companies including Gilead Sciences (CAR-T leader), Novartis, Juno Therapeutics/Celgene, and numerous private cell therapy developers. Mustang's clinical-stage status and limited resources place it at a disadvantage relative to established CAR-T manufacturers and larger biotech competitors with proven manufacturing and commercial capabilities.
Industry Context
Mustang Bio, Inc. operates in Cell and gene therapy development.
Key facts
Founded: 2015 · Headquarters: Worcester, US · Employees: N/A · Revenue: N/A · Market cap: $5.77M